0001169245-22-000067.txt : 20220520 0001169245-22-000067.hdr.sgml : 20220520 20220520164713 ACCESSION NUMBER: 0001169245-22-000067 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210818 FILED AS OF DATE: 20220520 DATE AS OF CHANGE: 20220520 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hutson Nancy J CENTRAL INDEX KEY: 0001379222 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38697 FILM NUMBER: 22948349 MAIL ADDRESS: STREET 1: 64 MONTAUK AVENUE CITY: STONINGTON STATE: CT ZIP: 06378 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PhaseBio Pharmaceuticals Inc CENTRAL INDEX KEY: 0001169245 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 030375697 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 GREAT VALLEY PARKWAY STREET 2: SUITE 30 CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: (610) 981-6500 MAIL ADDRESS: STREET 1: 1 GREAT VALLEY PARKWAY STREET 2: SUITE 30 CITY: MALVERN STATE: PA ZIP: 19355 FORMER COMPANY: FORMER CONFORMED NAME: Phase Biosciences Inc DATE OF NAME CHANGE: 20061013 FORMER COMPANY: FORMER CONFORMED NAME: DT BIOSCIENCES INC DATE OF NAME CHANGE: 20020315 4/A 1 wf-form4a_165307960124153.xml FORM 4/A X0306 4/A 2021-08-18 2021-08-19 0 0001169245 PhaseBio Pharmaceuticals Inc PHAS 0001379222 Hutson Nancy J C/O PHASEBIO PHARMACEUTICALS, INC. 1 GREAT VALLEY PARKWAY, SUITE 30 MALVERN PA 19355 1 0 0 0 Common Stock 2021-08-18 4 P 0 3000 3.08 A 4000 I Held in an individual retirement account for the benefit of the Reporting Person Common Stock 33760 D The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.07 to $3.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. Amended to report direct share ownership. /s/ John P. Sharp, Attorney-in-fact 2022-05-20